Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Abroad (travel likely)RecruitingPHASE2
Conditions
Multiple Myeloma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Miami, Miami, Florida, United States
Contact: Principal Investigator (Carl O Landgren, MD, PhD)
Study leads
Carl O Landgren, MD, PhD
Principal Investigator
University of Miami